Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Adaptate Biotherapeutics Ltd.
Headquarters: London, United Kingdom
Website: https://www.adaptate.com
Year Founded: 2019
Status: Private
BioCentury | Jan 13, 2022
Deals
Century deal hands BMS another chance to be an early mover, with iPS immune cells, γδ T
BMS’s Vessey aims to improve on existing cell therapies, break new ground with $150M deal
BioCentury | Jan 10, 2022
Deals
Adaptate takeout is Takeda’s latest move in γδ sector
Build-to-buy deal gives Takeda set of γδ antibodies, paired with existing T cell therapy holdings
BioCentury | Nov 16, 2021
Product Development
With trial starts and a takeout, γδ therapies start coming of age
Company data at SITC and ASH for antibodies and cell therapies directing γδ T cells to kill cancers
BioCentury | Mar 12, 2020
Management Tracks
Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more
BioCentury | Feb 28, 2020
Emerging Company Profile
Lava: better safety for bispecifics with γδ T cell engagement
Lava expects its γδ T cell bispecifics will have same efficacy, better safety than CD3 bispecifics
Items per page:
1 - 6 of 6